Leonard Schleifer, Regeneron CEO (Photo by: Adam Jeffery/CNBC/NBCU Photo Bank via Getty Images)
August 3, 2023 11:48 AM EDT
Pharma
FDA+
Manufacturing

Re­gen­eron plans for quick re­de­ci­sion on CRL for high­er dose of Eylea

Tyler Patchen

News Reporter

Re­gen­eron saw its stock price rise by more than 6% on Thurs­day af­ter an­nounc­ing a faster than ex­pect­ed de­ci­sion on its soon-to-be re­sub­mit­ted ap­pli­ca­tion for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times